bullish
Ajanta Pharma (AJP IN): Branded Generics Focus Ensures Consistent Growth
391 Views16 Sep 2022 21:21
SUMMARY
- Ajanta Pharma (AJP IN) has a well-diversified business model in terms of markets and therapies. The company’s largest revenue contributing segment, branded generics is seeing healthy double-digit revenue growth.
- Ajanta focuses on limited competition product in US. Going forward, the US business will see accelerated growth, driven by new launches. Ajanta plans to file 10–12 ANDAs during FY23.
- Ajanta has taken 1% price increase across all its market, which should drive margin improvement in coming quarters. The company has guided for EBITDA margin of 26–27% for FY23.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Ajanta Pharma (AJP IN): Stellar Q4 Performance; INR3B Buyback Plan Announced06 May 2024
- Ajanta Pharma (AJP IN): Starts FY24 With Healthy Branded Generics Growth and Improving Margins25 Sep 2023
- Ajanta Pharma (AJP IN): Branded Generics Focus Ensures Consistent Growth16 Sep 2022
x